Autologous Co-stimulation-impaired Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy: A Sequential Open Label Phase IB Safety Assessment/ Randomized, Double-blind Phase IIA Efficacy Trial to Maintain and Improve Functional Beta Cell Mass in New Onset Disease T1DM Patients
Latest Information Update: 03 Oct 2021
At a glance
- Drugs DV 100 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors DiaVacs
- 12 Feb 2014 Profil Institute for Clinical Research will collaborate with DiaVacs to conduct this trial, according to a DiaVacs media release.
- 10 Oct 2013 New trial record